Home › Breast Cancer › Oregon
Breast Cancer clinical trials in Oregon
40 studies for Breast Cancer are looking for participants at sites in Oregon.
Cities in Oregon
- Portland32 studies
- Beaverton8 studies
- Eugene7 studies
- Salem5 studies
- Bend4 studies
- Corvallis3 studies
- Gresham3 studies
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05877599Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Good Samaritan Regional Medical Center, Corvallis
- Oncology Associates of Oregon PC, Eugene
- Northwest Cancer Specialists, Portland
- and 1 more
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 29, 2026 · NCT05827081Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Oregon Health and Science University, Portland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07007559A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Providence Portland Medical Center ( Site 0044), Portland
- Providence St. Vincent Medical Center ( Site 0081), Portland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312176A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Northwest Cancer Specialists (Compass Oncology) ( Site 8010), Tigard
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06966700A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06618287Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Portland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07085767A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 22, 2026 · NCT07287098A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Good Samaritan Regional Medical Center, Corvallis
- Oncology Associates of Oregon, Eugene
- Oregon Health and Science University, Portland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07174336ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- St Charles Bend Cancer Center, Bend
- Providence Portland Medical Center, Portland
- St. Charles Cancer Center - Redmond, Redmond
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07173751The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Providence Cancer Institute Franz Clinic, Portland
- Providence Cancer Institute Franz Clinic, Portland
- Oregon Oncology Specialists, Salem
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06492616Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Providence Portland Medical Center, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Northwest Cancer Specialists (Compass Oncology) ( Site 8003), Tigard
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06797635A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Providence Cancer Institute, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06253871A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Oncology Associates of Oregon, P.C, Eugene
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT07100106Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Oregon Health & Science University, Knight Cancer Institute, Portland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06982521A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Providence Portland Medical Center, Portland
- Providence Oncology and Hematology Cancer Clinic - Westside;Investigation Drug Services Pharmacy, Portland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06790693Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- and 8 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- and 10 more
RecruitingPhase 3
Ages 18 to 60 · Women · Updated Sep 2, 2026 · NCT05879926A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06242470A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Willamette Valley Cancer Institute, Eugene
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06926868Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Hematology Oncology Associates, Medford
- Compass Oncology - Northwest Cancer Specialists, Tigard
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Aug 6, 2026 · NCT05232916E-Mindfulness Approaches for Living After Breast Cancer
- Saint Charles Health System, Bend
- Providence Hood River Memorial Hospital, Hood River
- Providence Newberg Medical Center, Newberg
- and 6 more
RecruitingPhase 3
Ages 18 to 50 · All sexes · Updated Aug 4, 2026 · NCT06748222Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Oncology Associates of Oregon, P.C., Eugene
- Compass Oncology - Rose Quarter, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors
- Samaritan Pastega Regional Cancer Center, Corvallis
RecruitingPhase 1
Ages 18 and older · Women · Updated Jul 17, 2026 · NCT07055854Identifying and Caring for Individuals With Inherited Cancer Syndrome
- Providence Portland Medical Center, Portland
- OHSU Knight Cancer Institute, Portland
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT04494945First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
- Oncology Associates of Oregon, Springfield
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT07558733177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
- OHSU Knight Cancer Institute, Portland
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Jun 5, 2026 · NCT04529044I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Oregon Health & Science Institute (OHSU), Portland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT01042379De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Clackamas Radiation Oncology Center, Clackamas
- Legacy Mount Hood Medical Center, Gresham
- Providence Newberg Medical Center, Newberg
- and 5 more
RecruitingPhase 3
Ages 50 to 70 · All sexes · Updated Apr 23, 2026 · NCT04852887Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Kaiser Permanente Northwest, Portland
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 17, 2026 · NCT06418204cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Jan 20, 2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Kaiser Permanente Northwest, Portland
- Oregon Health and Science University, Portland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 8, 2025 · NCT03418961MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- Willamette Valley Cancer Institute and Research Center, Eugene
- Legacy Good Samaritan Medical Center, Portland
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 20, 2025 · NCT03053193EMBRACE: Exercising Together
- OHSU Knight Cancer Institute, Portland
RecruitingPhase 2Healthy volunteers welcome
Ages 18 and older · All sexes · Updated May 29, 2025 · NCT06049355CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Oregon Oncology Specialists, Salem
RecruitingObservational study
Ages 18 and older · Women · Updated Jan 7, 2025 · NCT06230185From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.